Eberhard Grube1, Nicolas M Van Mieghem2, Sabine Bleiziffer3, Thomas Modine4, Johan Bosmans5, Ganesh Manoharan6, Axel Linke7, Werner Scholtz8, Didier Tchétché9, Ariel Finkelstein10, Ramiro Trillo11, Claudia Fiorina12, Antony Walton13, Christopher J Malkin14, Jae K Oh15, Hongyan Qiao16, Stephan Windecker17. 1. Department of Medicine, University of Bonn, Bonn, Germany. Electronic address: grubee@aol.com. 2. Department of Cardiology, Erasmus Medical Centre Rotterdam, Rotterdam, the Netherlands. 3. Department of Cardiovascular Surgery, German Heart Center, Munich, Germany. 4. Department of Cardiovascular Surgery, Lille University Hospital, Lille, France. 5. Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium. 6. Regional Cardiology Department, Royal Victoria Hospital, Belfast, United Kingdom. 7. Department of Internal Medicine/Cardiology, Heart Centre, University of Leipzig, Leipzig, Germany. 8. Department of Interventional Cardiology, Heart and Diabetes Centre, NRW Bad Oeynhausen, Bad Oeynhausen, Germany. 9. Department of Cardiology, Clinique Pasteur Toulouse, Toulouse, France. 10. Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 11. Department of Cardiology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain. 12. Cardiothoracic Department, Spedali Civili Brescia, Brescia, Italy. 13. Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia. 14. Department of Cardiology, Leeds General Infirmary, Leeds, United Kingdom. 15. Mayo Clinic, Rochester, Minnesota. 16. Statistical Services, Medtronic, Minneapolis, Minnesota. 17. Department of Cardiology, University Hospital Bern, Bern, Switzerland.
Abstract
BACKGROUND: Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. OBJECTIVES: This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice. METHODS: The FORWARD (CoreValve Evolut R FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study. An independent clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2 definitions. An independent echocardiographic core laboratory evaluated all echocardiograms. From January 2016 to December 2016, TAVR with the next-generation self-expanding THV was attempted in 1,038 patients with symptomatic, severe AS at 53 centers on 4 continents. RESULTS: Mean age was 81.8 ± 6.2 years, 64.9% were women, the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 5.5 ± 4.5%, and 33.9% of patients were deemed frail. The repositioning feature of the THV was applied in 25.8% of patients. A single valve was implanted in the proper anatomic location in 98.9% of patients. The mean aortic valve gradient was 8.5 ± 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge. All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days. The expected-to-observed early surgical mortality ratio was 0.35. A pacemaker was implanted in 17.5% of patients. CONCLUSIONS: TAVR using the next-generation THV is clinically safe and effective for treating older patients with severe AS at increased operative risk. (CoreValve Evolut R FORWARD Study [FORWARD]; NCT02592369).
BACKGROUND: Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. OBJECTIVES: This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice. METHODS: The FORWARD (CoreValve Evolut R FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study. An independent clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2 definitions. An independent echocardiographic core laboratory evaluated all echocardiograms. From January 2016 to December 2016, TAVR with the next-generation self-expanding THV was attempted in 1,038 patients with symptomatic, severe AS at 53 centers on 4 continents. RESULTS: Mean age was 81.8 ± 6.2 years, 64.9% were women, the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 5.5 ± 4.5%, and 33.9% of patients were deemed frail. The repositioning feature of the THV was applied in 25.8% of patients. A single valve was implanted in the proper anatomic location in 98.9% of patients. The mean aortic valve gradient was 8.5 ± 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge. All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days. The expected-to-observed early surgical mortality ratio was 0.35. A pacemaker was implanted in 17.5% of patients. CONCLUSIONS: TAVR using the next-generation THV is clinically safe and effective for treating older patients with severe AS at increased operative risk. (CoreValve Evolut R FORWARD Study [FORWARD]; NCT02592369).
Authors: Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Marvin H Eng; Gaetano Paone; Bradley G Leshnower; Mark Reisman; Lowell Satler; Ron Waksman; Marcus Y Chen; Annette M Stine; Xin Tian; Danny Dvir; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: Teresa Alvarado; Fernando Rivero; Guillermo Diego; Marcos García-Guimaraes; Jorge Salamanca; Pablo Díez-Villanueva; Javier Cuesta; Paula Antuña; Jesús Jiménez-Borreguero; Fernando Alfonso Journal: J Thorac Dis Date: 2021-07 Impact factor: 2.895
Authors: Francesco Moroni; Lorenzo Azzalini; Lars Sondergaard; Guilherme F Attizzani; Santiago García; Hani Jneid; Mamas A Mamas; Rodrigo Bagur Journal: J Am Heart Assoc Date: 2022-06-14 Impact factor: 6.106
Authors: Rajat Datta; Prashant Bharadwaj; Naveen Aggarwal; G Keshavamurthy; Prafull Sharma; Nitin Bajaj; Vijay Bohra; V S Guleria; Balbir Singh Journal: Med J Armed Forces India Date: 2022-02-01